June 2018

Less than half of bowel cancers are found early and Rhythm Biosciences could help change this

Only 46 per cent of colorectal cancers are diagnosed at early stages when it is most curable, according to new data from the federal government. Cancer Australia’s latest “stage at diagnosis” data — the extent to which a cancer has spread when it’s diagnosed — shows that of the top five cancers, colorectal cancer came in second-worst behind lung cancer for early stage detection. Read more

June 2018

Rhythm Biosciences’ 15-year journey from idea to cancer diagnosis

The survival rate for bowel cancer is 90 per cent if it’s caught early. But people are reluctant to take stool tests — which results in more deaths. In 2015, 4346 Australians died from bowel cancer — the second-highest number of cancer deaths after lung cancer. More than 15,000 new cases are diagnosed in Australia each year. Melbourne-based Rhythm Biosciences (ASX:RHY) is trying to change that with a simple mission: create a bowel cancer test that is simpler and more acceptable to the squeamish. Read more

June 2018

New Bowel Cancer Tech could Save Lives as US Experts Call for Younger Testing

The message about the need to check for bowel cancer isn’t getting through, with screening rates still lower than half of all people who should be taking the test. That suggests it’s time for a new approach to screening. Last week the American Cancer Society lowered the recommended age for bowel cancer screening from 50 to 45 after finding incidences of bowel cancer were increasing among younger adults in the at-risk age group. Read more

June 2018

Rhythm Biosciences Moves Closer to Early Colon Cancer Detection after Successful Tests

Leading biotech Rhythm Biosciences has passed a crucial phase in the development of an improved colon cancer blood test after four new test preparations successfully came through initial screening. Rhythm Bio (ASX:RHY) is working to develop a simple, easy-to-use blood test for colorectal cancer. It’s a critically important project because not enough people are undergoing screening early enough to find out if they have the disease. Read more